We are live on
!
Find out more
FM
Frazier Management Portfolio holdings
AUM
$1.12M
1-Year Est. Return
151.58%
This Fund
S&P 500
This Quarter
Est. Return
+24.15%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
+$185M
(+17%)
Cap. Flow
+$75.5M
Cap. Flow
% of AUM
5.81%
Top 10 Holdings %
Top 10 Hldgs %
78.61%
Holding
39
New
8
Increased
5
Reduced
3
Closed
4
Avg Time Held
5.4
quarters
Top 10 Avg Time Held
5
quarters
Top 20 Avg Time Held
6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tarsus Pharmaceuticals
TARS
|
+$54.6M |
| 2 |
Sutro Biopharma
STRO
|
+$16.6M |
| 3 |
FLACU
Frazier Lifesciences Acquisition Corporation Unit
FLACU
|
+$15.7M |
| 4 |
EPZM
Epizyme, Inc
EPZM
|
+$9.02M |
| 5 |
Molecular Templates, Inc.
MTEM
|
+$8.29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AnaptysBio
ANAB
|
+$34.4M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
+$13.1M |
| 3 |
Cidara Therapeutics
CDTX
|
+$3.74M |
| 4 |
vTv Therapeutics
VTVT
|
+$1.88M |
| 5 |
Minerva Neurosciences
NERV
|
+$1.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.8% |
| 2 | Miscellaneous | 1.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
DELISTED
Molecular Templates, Inc.
MTEM
| $7.91M | 0.61% |
+56,127
| New | +$8.29M |
2020 Q4
0 quarters
|
|
27
Scholar Rock
SRRK
$4.93B
| $7.45M | 0.57% |
+153,500
| New | +$5.57M |
2020 Q4
0 quarters
|
|
|
ALNA
28
DELISTED
Allena Pharmaceuticals
ALNA
| $4.26M | 0.33% |
3,330,373
| – | – |
2017 Q4
12 quarters
|
|
|
BLU
29
DELISTED
BELLUS Health Inc.
BLU
| $3.9M | 0.3% |
1,296,743
| – | – |
2020 Q3
1 quarter
|
|
|
SRRA
30
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $3.25M | 0.25% |
202,803
| – | – |
2015 Q4
20 quarters
|
|
31
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $2.46M | 0.19% |
+241,000
| New | +$2.64M |
2020 Q4
0 quarters
|
|
32
ARS Pharmaceuticals
SPRY
$403M
| $1.66M | 0.13% |
+35,750
| New | +$1.19M |
2020 Q4
0 quarters
|
|
33
DELISTED
Iterum Therapeutics
ITRM
| $1.52M | 0.12% |
102,554
| – | – |
2018 Q2
10 quarters
|
|
|
NBRV
34
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $1.03M | 0.08% |
17,026
| – | – |
2018 Q3
9 quarters
|
|
|
35
Minerva Neurosciences
NERV
$120M
| $144K | 0.01% |
7,693
-61,057
| -89% | -$1.54M |
2020 Q3
1 quarter
|
|
|
36
DELISTED
Cidara Therapeutics
CDTX
| – | – |
-65,613
| Closed | -$3.74M | – |
|
|
37
vTv Therapeutics
VTVT
$112M
| – | – |
-26,550
| Closed | -$1.88M | – |
|
|
BLCM
38
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| – | – |
-105,144
| Closed | -$691K | – |
|
|
ETTX
39
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
| – | – |
-199,953
| Closed | -$408K | – |
|
Similar funds
ACMV
FRCMI
DB
NAM
AP
ID
CI
DIF
Frazier Management's Q4 2020 Portfolio in Review
As of Q4 2020, Frazier Management held 39 positions worth $1.3B, up 17% from $1.11B the previous quarter. Its ten largest holdings account for 79% of the portfolio.
Frazier Management deployed $75.5M of net new capital in Q4 2020, opening 8 new positions and adding to 5 existing holdings. Its largest new stake was Tarsus Pharmaceuticals: 1,917,157 shares worth $79.2M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was AnaptysBio, an estimated $34.4M trimmed.
- Frazier Management's largest Q4 2020 buy was Tarsus Pharmaceuticals: 1,917,157 shares worth $79.2M.
- Frazier Management added most to Regenxbio in Q4 2020, an estimated $5.86M increase.
- Frazier Management's biggest Q4 2020 reduction was AnaptysBio, cutting an estimated $34.4M.
- Frazier Management fully exited Cidara Therapeutics in Q4 2020, selling an estimated $3.74M.
- Frazier Management's ten largest holdings make up 79% of its $1.3B portfolio in Q4 2020.
- Frazier Management opened 8 new positions and closed 4 in Q4 2020.
- Frazier Management's portfolio value rose 17% quarter-over-quarter to $1.3B.
Based on Frazier Management's 13F filing for Q4 2020, filed 11 Feb 2021.